Pharma Thriller: ImClone’s Secret Suitor Remains Cloaked In Mystery
This article was originally published in The Pink Sheet Daily
Executive Summary
Eli Lilly is rumored to be the admirer, offering $70 per share to outbid rival Bristol-Myers Squibb.